EBV and Lymphomagenesis: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Jason Zhu and Version 1 by Daniel Sausen.

The clinical significance of Epstein–Barr virus (EBV) cannot be understated. Not only does it infect approximately 90% of the world’s population, but it is also associated with numerous pathologies. Diseases linked to this virus include hematologic malignancies such as diffuse large B-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, primary CNS lymphoma, and NK/T-cell lymphoma, epithelial malignancies such as nasopharyngeal carcinoma and gastric cancer, autoimmune diseases such as multiple sclerosis, Graves’ disease, and lupus. While treatment for these disease states is ever evolving, much work remains to more fully elucidate the relationship between EBV, its associated disease states, and their treatments.

  • EBV
  • latent proteins
  • cancer

1. Diffuse Large B-Cell Lymphoma

Epstein–Barr virus (EBV)+ diffuses large B-cell lymphoma (DLBCL); not otherwise specified (NOS) is an aggressive lymphoma variant with a relatively poor prognosis [84][1]. This entity was originally associated with the elderly [85][2], leading to the hypothesis that the immune senescence that naturally occurs with aging may play a role in its oncogenesis [86][3]. The aging immune system develops many changes, including but not limited to chronic low-level inflammation, a diminished ability to handle pathogens, and an increased risk of autoimmunity and cancer [87][4]. DLBCL has since been recognized as an entity that can affect younger individuals as well [88,89][5][6].
EBV+ DLBCL typically expresses a type III latency program [84][1], and EBNA2 has been shown to play a role in its oncogenesis. One way in which this is accomplished is through the induction of PD-L1. Notably in one study, when EBNA2 expression was induced by infecting the EBV negative DLBCL cell lines U2932 and SUDHL5 with EBV, PD-L1 expression was upregulated in both lines. When tested in EBNA2-transfected U2932 cells, miR-34a, a cellular miRNA, was downregulated [53][7]. Notably, miR-34a expression is inversely correlated with PD-L1 expression [90][8]. miR-34a overexpression in this infected cell line resulted in significant tumor cell death, indicating that the EBNA2-mediated downregulation of miR-34a and subsequent upregulation of PD-L1 suppresses the immunogenicity of infected cells. Consistent with these results, EBV+ DLBCL cells obtained from patients demonstrated higher PD-L1 expression. The increase in PD-L1 expression in EBNA2+ samples when compared to EBNA2− samples was particularly conspicuous when assessing the number of cells that stained strongly for PD-L1 [53][7].
S1PR2 Is a sphingosine receptor that has been shown to prevent B-cell migration out of germinal centers [91][9]. Indeed, S1PR2 signaling is inactivated in DLBCL [92][10]. A recent set of experiments has implicated LMP1 in dysregulated S1PR2 signaling. Samples of EBV+ DLBCL with intact LMP1 expression were more likely to lack S1PR2 than tumors not expressing LMP1. Downstream effects of the reduced S1PR2 expression include constitutive PI3K path expression [93][11]. In mouse models, LMP1 has also been shown to cooperate with Ebf1 and Rel to promote lymphomagenesis. Following the induction of LMP1 expression in CD43− B cells from R26LMP1stopf mice, retroviruses carrying either Ebf1 or Rel genes were introduced into the cell. LMP1-expressing cells transformed into mouse lymphoblastoid cell lines with the addition of either Ebf1 or Rel, but not with the control. The authors further showed that loss of plasma cell differentiation secondary to Ebf1 activation, or as yet undiscovered events in Relhigh cells, is a key element of LMP1 lymphomagenesis [94][12]. Notably, LMP1 was previously implicated in preventing B-cell differentiation into plasma cells by downregulating BLIMP1α [95][13].
Murine experiments also demonstrated that LMP1 collaborates with LMP2A to promote early lymphomagenesis, but that neither protein is absolutely required. Working with Humanized NOD/LtSz-scid/IL2Rγnull mice, Ma et al. demonstrated that deleting LMP1 and LMP2A simultaneously did not inhibit the development of lymphomas. However, the frequency with which lymphomas developed was reduced, and tumors took longer to develop [96][14].
Nagel et al. recently demonstrated that NKL homeobox gene activity is dysregulated in DLBCL [97][15]. Expression profiling of DOHH-2 cells, a DLBCL line with <5% EBV positivity, unsurprisingly demonstrated altered expression patterns of several B-cell genes between the EBV+ and EBV− subsets, including the downregulation of BCL6, BACH2, and IL4R and increased levels of IRF4, MIR155HG, and PRDM1. The NKL homeobox genes HLX, NKX6-3, and MSX1 also demonstrated altered expression profiling in DOHH-2 cells, a difference that was particularly notable in HLX and NKX6-3 cells. Subsequent experiments demonstrated that EBV-mediated STAT3 upregulation increased HLX activity. Notably, it was demonstrated that HLX inhibits B-cell differentiation factors SPIB and IL4R. The authors further showed that EBV inhibited apoptosis in the presence of etoposide, potentially through the activation of HXL and subsequent downregulation of the pro-apoptotic gene BCL2L11/BIM [98][16].
EBV+ DLBCL expresses increased levels of NF-κB when compared to EBV− DLBCL [99,100][17][18]. Indeed, nuclear staining for the NF-κB subunits p105/p50 and p100/p52 showed that 79% of cases were positive for the former, 74% for the latter, and 63% were positive for both subunits. These results are consistent with NF-κB activation through both the classical and alternative pathways. The authors concluded that EBV may play a role in activating the NF-κB pathway in DLBCL [99][17].
In summary, EBV latent proteins stimulate a wide variety of changes that promote the formation of DLBCL, such as the upregulation of PD-L1, which has major implications in treatment. Management will be discussed in the next section. It also stimulates alteration in S1PR2 signaling, which has significant downstream effects, and upregulation of STAT3. These changes cumulatively promote the formation of DLBCL.

Management

Treatment for DLBCL includes rituximab (anti-CD20 monoclonal antibody), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP R-CHOP has demonstrated less significant responses in EBV+ DLBCL than in EBV− DLBCL patients [7][19]. Currently, there are no accepted treatments targeting EBV+ DLBCL, and the development of such targeted treatment remains elusive [101,102][20][21]. A phase II trial used the knowledge that LMP1 has a similar function to that of the BTK-dependent B-cell receptor and used ibrutinib, a BTK inhibitor in combination with R-CHOP. While effective, it did not demonstrate a significant improvement when compared to R-CHOP. It was, however, associated with serious toxicity and treatment-related death in older patients [103][22]. POLARIX, a double-blind phase III trial, evaluated a modified R-CHOP regimen (pola-R-CHP) where polatuzumub vedotin (anti-79b monoclonal antibody) replaced vincristine. Patients receiving pola-R-CHP had lower rates of disease progression/relapse than those receiving R-CHOP [104][23]. Bortezomib is another agent that, when tested in mice, induced the apoptosis of EBV-transformed B cells and prolonged survival following the inoculation of those mice with the afore-mentioned transformed B cells [105][24]. Lenalidomide exhibited antitumor activity against DLBCL cells, particularly ABC-DLBCL cells. It was postulated that this difference arises through the inhibition of IRF4 expression and BCR-NF-κB signaling pathway in a cereblon-dependent manner [106][25]. PD-L1 is associated with a poor prognosis in aggressive lymphomas, and PD-L1 is commonly upregulated in EBV+ lymphoproliferative disorders (LPD). Nivolumab, a fully human IgG4 monoclonal anti-PD-1 antibody, is both safe and effective in lymphoid malignancies. A phase II study including nine patients hypothesized that PD-1 blockade may treat EBV+ LPD and NHL by reversing tumor-specific T-cell inactivation. ORR was 60% (three out of five) and CR was 40% (two out of five) in the LPD group [107][26]. The adoptive transfer of antigen-specific T lymphocytes is emerging as a potential avenue for the treatment of virus-associated malignancies, including EBV-associated malignancy [108][27]. In a cohort of 101 patients assessing anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, there was an objective response rate of 76%. Overall, 47% of patients experienced a complete response, and progression-free survival at 1 month was 92%. It was 53% at 3 months [109][28]. A trial by Wudhikarn et al. assessed the efficacy of CAR T-cell therapy in relapsed/refractory DLBCL in patients who had no evidence of disease at the time of CAR T-cell treatment. A total of 24 patients received tisagenlecleucel and 9 received axicabtagene ciloleucel. Event-free survival was 59.6% and overall survival was 81.3% [110][29]. There are several ongoing studies for the treatment of EBV+ DLBCL, such as the NAVAL-1 (nanatinostat in combination with valganciclovir) phase II trial. Nanatinostat targets specific class I HDAC isoforms. Class I HDAC suppression results in the activation of the lytic gene BGLF4 and subsequent activation of ganciclovir [111,112][30][31]. The combination of nanatinostat and valganciclovir was further analyzed by Haverkos et al. in a phase Ib/II trial that showed a 67% overall response rate, including a 33% complete response rate in DLBCL [112][31]. Another study seeking to develop EBV-directed therapy is a phase II, prospective, multi-center study assessing the combination of Sintilimab (an anti-PD-1 antibody) and R-CHOP in previously untreated patients with EBV+ DLBCL, NOS [113][32].

2. Classic Hodgkin Lymphoma

Hodgkin lymphoma is a malignancy characterized by the presence of Hodgkin cells, which are mononucleated, and Reed–Sternberg cells, which are binucleated. These cells express clusters of differentiation (CD) 20, 30, and occasionally CD15. They are thought to originate from pre-apoptotic germinal center B cells [114][33]. Notably, these cells are relatively rare compared to the inflammatory tumor microenvironment in which they exist [115][34]. EBV’s relation to such cells has long been known [116][35]. Indeed, it is estimated that approximately 30% of classical Hodgkin lymphoma (cHL) cases in the Western world are associated with EBV [117][36], and recent research has shown that the lymphomagenesis of a subset of EBV− lymphomas may in fact be related to EBV [118][37]. Notably, this statistic does not reflect the nodular lymphocyte-predominant variant of Hodgkin lymphoma, which can have EBV+ lymphocyte-predominant cells, but is not typically EBV-associated [119][38].
As was previously mentioned, Hodgkin lymphoma is characterized by a type II latency program [39]. LMP1 plays a key role in lymphomagenesis, in part through the reprogramming of germinal center (GC) B cells so they more closely resemble a Hodgkin Reed–Sternberg cell (HRS) phenotype [120][40]. Of 20,551 GC B-cell genes examined on the HG-U133 plus microarray, LMP1 upregulated 622 and downregulated 1304. Common pathways with altered expression in both LMP1-infected cells and HRS cells include NF-κB, AP-1/ATF, STAT, and PI3K as well as FAS/CD95 and anti-apoptotic genes. Pro-apoptotic genes were downregulated. A total of 881 genes were changed by both LMP1 and HRS cells [120][40]. LMP1 downregulated B-cell-specific genes and upregulated the B-cell-specific gene suppressor ID2 [120][40]. Loss of B-cell-specific genes is a hallmark of HRS cells [121][41]. Notably, many of the pathways upregulated by LMP1, such as NF-κB and JAK/STAT, are also upregulated in HRS cells [115][34]. LMP1 has additionally been shown to induce CD137 in HRS cells through the activation of the PI3K-AKT-mTOR signaling axis [122][42]. CD137 activity was previously shown to contribute to immune evasion in Hodgkin lymphoma by inhibiting T-cell activation through downregulation of CD137 ligand [123][43]. LMP1 expression was further demonstrated to correlate with the expression of the chemokines CCL17 and CCL22 production in HRS [124][44]. These chemokines have previously been shown to enhance regulatory T-cell (Treg) recruitment in various EBV-related malignancies [125,126][45][46]. In addition, LMP1 expression plays a role in regulating autophagy. Hodgkin lymphoma cells expressing LMP1 were better able to adapt to starvation-induced autophagic stress [127][47].
Alterations in the gene expression are a hallmark of lymphoma and of cancer in general [128,129,130][48][49][50]. LMP2A also induces changes in B-cell gene transcription that mimic Reed–Sternberg cells [131][51]. Indeed, LMP2A was noted to result in the differential expression of 159 genes in LMP2A-expressing BJAB cells and 139 genes in EBV-infected LCLs. These changes impacted genes involved in multiple cellular processes including ubiquitination, transcription, and cell cycle/apoptosis. Interestingly, genes implicated in RNA/DNA were impacted in human cell lines, implying that LMP2A can cause deregulated DNA replication/gene transcription [131][51]. Furthermore, Anderson and Longnecker used a mouse model to demonstrate that LMP2A acts through the Notch1 pathway to impact B-cell development [132][52].
Another way in which LMP2A contributes to the pathogenesis of Hodgkin’s lymphoma is through its impact on the tumor microenvironment (TME) [133][53]. The TME in cHL is highly complex and plays many roles, including immune suppression, survival, and proliferation. One mechanism by which this occurs is by attracting immune cells into the TME [117][36]. LMP2A expression was highly correlated with the expression of the cytokine MIP-1α [133][53]. Cells containing mutant EBV whose LMP2A did not bind SYK did not upregulate MIP-1α expression. The same set of experiments demonstrated that LMP2A upregulates MIP-1α expression through the activation of Syk/PI3K/NF-κB signaling [133][53].
EBNA1 has also been implicated in the pathogenesis of cHL, for example, through promoting the survival of Reed–Sternberg cells [134][54]. For example, protein tyrosine phosphatase receptor kappa (PTPRK) expression was shown to be downregulated in EBV infection. Mechanistically, it was determined that this downregulation was accomplished through the downregulation of SMAD2. These results are significant because PTPRK is a tumor suppressor protein. Indeed, the downregulation of PTPRK mRNA and protein resulted in a significant increase in both cell viability and proliferation. EBV+ cHL tumor cells demonstrated more frequent downregulation of PTPRK than EBV− cHL tumor cells [135][55]. Furthermore, EBV increases the expression of CCL20 to promote Treg migration. This allows EBV to recruit Tregs to the TME, which provides a mechanism by which EBV-infected cells can downregulate the anti-tumor immune response [136][56].
In summary, EBV promotes a rather dramatic change in B cells to promote the pathogenesis of cHL, including a wholesale reprogramming of genetic expression to more closely resemble a HRS phenotype. Changes include alterations in numerous pathways such as anti-apoptotic paths, FAS/CD95, and STAT. It also plays a role in immune evasion. LMP2A contributes to the remodeling of B cells to more closely mimic the transcription pattern of HRS cells. It also alters the TME, which has numerous critical roles in immune suppression, survival, and proliferation. EBNA1 also contributes to cHL pathogenesis, for example, through its pro-survival effects on HRS cells.

Management

The initial treatment of Hodgkin lymphoma depends on disease stage and prognostic factors. Patients are divided into three groups: patients with early-stage disease with favorable prognostic factors, patients with limited-stage disease and unfavorable prognostic factors, and those with advanced-stage disease [137][57]. Combination chemoradiotherapy remains integral to the treatment of patients with early disease and either favorable or unfavorable factors. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), and MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) are some of the chemotherapy regimens used along with radiation depending on disease stage. Patients with advanced disease receive chemotherapy alone [137][57]. Detecting EBV within cHL may help confirm diagnosis but does not influence therapeutic selection. [18,115][34][58]. In general, outcomes are poor in the elderly [138][59], and an EBV+ status is associated with even worse prognosis [139][60]. EBV infection constitutes another means for PD-L1 induction in cHL, and PD-1 blockade represents a possible avenue for targeted therapy. [140][61]. Brentuximab vedotin, an anti-CD30 antibody, is another therapy that has been examined in the setting of cHL [141][62]. For example, a recent phase I–II trial examined this drug in combination with nivolumab in the setting of relapsed/refractory cHL. Patients could receive an autologous stem cell transplant (ASCT), but did not have to, following therapy. The objective response rate was 85%, including a 67% complete response rate. Overall survival was 93% at 3 years [142][63]. The phase II HOVON/LLPC Transplant bRaVE trial assessed its efficacy in relapsed/refractory cHL in combination with dexamethasone, high-dose cytarabine, and cisplatin. Patients with partial/complete response went on to receive an autologous peripheral blood stem-cell transplant. 42 of 52 patients experienced a metabolic complete response prior to transplant while another 5 had a partial response prior to transplant. Progression free survival was 74%, and overall survival was 95% at 2 years [143][64]. Brentuximab vedotin’s role in stage III/IV cHL has also been examined. The Echelon-1 study demonstrated that brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine demonstrated greater clinical efficacy than ABVD, with a 3-year progression-free survival of 83.1% vs. 76.0%, respectively [144][65]. CAR T cells have likewise been shown to have potential as a therapeutic modality in cHL [145][66]. For example, Ramos et al. assessed its efficacy in patients with previously treated cHL. Patients had received an average of 7 previous lines of chemotherapy. Of the 32 patients analyzed, overall response was 72%, including a 59% complete response rate. 1 year progression-free survival was 36%, with an overall survival rate of 94% [146][67]. Another trial assessed the results of autologous stem cell transplantation in combination with anti-CD30 CAR T-cell therapy. 4 of 5 cHL patients experienced a complete response with the other experiencing a partial response. Responses were durable through the median follow up of 20.4 months [147][68]. Other therapies under study include vaccine approaches that have been developed based on recombinant virus proteins or virus peptides [148][69], EBV-specific cytotoxic T lymphocytes (CTLs) [148][69], therapies targeting specific EBV latent proteins [149][70], and EBNA1 inhibitors [150][71].

3. Burkitt Lymphoma

Burkitt lymphoma is a non-Hodgkin lymphoma that predominantly affects children. It is most strongly associated with a MYC oncogene translocation, although multiple other mutations play key roles as well, including those affecting TP53, ARF, and DDX3X [151][72]. The association between Burkitt lymphoma and EBV has long been known; indeed, it is the first cancer found to have viral contributions to its pathogenesis [151,152][72][73]. There are three forms: endemic, sporadic, and AIDS-Burkitt lymphoma. All three types can be associated with EBV [153][74]. Notably, at least for the endemic form, malaria is also involved in the development of Burkitt lymphoma [154][75].
Burkitt lymphoma is primarily associated with a type I latency pattern, meaning EBNA1 is the main protein expressed [37][76]. Indeed, there is some evidence that EBNA1 may be involved in the pathogenesis of Burkitt lymphoma [155][77]. For example, EBNA1 knockout using the transcription activator-like effector nuclease E1TN resulted in the death of cells infected by EBV. Furthermore, it was noted to cause progressive loss of EBV episomes from Burkitt lymphoma cells infected by EBV [156][78]. Wang et al. recently examined the role of EBNA1 in the pathogenesis of Burkitt lymphoma [157][79]. Vav1, a proto-oncogene, is aberrantly expressed in a multitude of B-cell malignancies, including non-Hodgkin lymphoma [158][80]. This molecule impacted apoptosis in the EBV+ cell lines RAJI and LCL-1 but not the EBV− cell line BJAB [157][79]. Cell lines with decreased Vav1 expression had increased levels of the pro-apoptotic BCL-2 protein Bim. It was subsequently shown that Vav1 binds to EBNA1 and that EBNA1 expression was inversely correlated with Bim expression. The implication is that the interaction between EBNA1 and Vav1 results in enhanced resistance to apoptosis through suppression of Bim [157][79]. EBNA3A and EBNA3C have also been shown to play a role in Bim suppression. This suppression was noted even in the setting of latently infected cells. EBNA3A and EBNA3C appear to accomplish this through downregulating Bim RNA. The survival advantage conferred by EBNA3A and EBNA3C was negligible in the absence of Bim [159][81].
EBV-associated Burkitt lymphoma has differential gene expression when compared to EBV− Burkitt lymphoma. It was recently shown that EBV miRNAs impact the molecular profile of Burkitt lymphoma. Indeed, 103 genes known to be viral miRNA targets were differentially expressed in EBV+ tumors when compared to EBV− tumors. These genes were involved in many key cellular processes, including transcription, gene expression, nucleotide/RNA metabolism, and apoptosis. Several were related to tumorigenesis, including TP53, TGFB, mTOR, and others besides [160][82]. The substantial impact of miRNAs corroborates studies demonstrating key roles for these molecules in Burkitt lymphoma cell survival [161][83]. Ectopic BART miRNA introduced into Burkitt lymphoma cell lines resulted in decreased apoptosis and promoted cell proliferation. It was shown that BART miRNAs target transcripts of CASP3 [161][83], a gene involved in apoptosis [162][84]. Subsequent experiments demonstrated that the 12 BARTs inhibited CASP3 transcripts, with BART22 responsible for the most significant repression [163][85]. Moreover, BART miRNAs stimulated B-cell transformation as well as survival and/or proliferation [161][83]. Furthermore, BARTs have been shown to inhibit host defenses in the setting of Burkitt lymphoma. For example, overexpression of miR-BART-6-3P resulted in a decreased expression of IL-6R. Furthermore, it acted synergistically with the cellular microRNA miR-197, which also targets IL-6R, to further downregulate IL-6R [164][86]. miR-BART-6-3P also acts synergistically with miR-142 to reduce the expression of both IL-6R and PTEN [165][87], a tumor suppressor that inhibits the PI3K/AKT/mTOR pathway [166][88].
In summary, Burkitt lymphoma is associated with type I latency. As such, EBNA1 is key to its pathogenesis. EBNA1 knockout results in the apoptosis of EBV-infected cells and leads to episomal loss in Burkitt lymphoma cells. Furthermore, it results in aberrant VAV1 expression, which ultimately enhances cell survival. EBV miRNAs significantly alter the gene expression of multiple cell processes including apoptosis, transcription, and gene regulation.

Management

The endemic subtype of Burkitt lymphoma is known to be universally associated with EBV, and EBV is detected in 25% to 40% of sporadic and immunodeficiency-associated cases [167][89]. Burkitt lymphoma is highly chemotherapy sensitive [167][89], and the commonly used regimens in the US include rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH); cyclophosphamide, doxorubicin, vincristine, methotrexate, ifosfamide, cytarabine, and etoposide (CODOX-M/IVAC); hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate, and cytarabine (hyper-CVAD) [167,168][89][90]. Low-dose adjusted R-EPOCH facilitates the treatment of elderly and HIV-positive patients by reducing the toxicity associated with higher intensity therapy. [169][91]. In patients with advanced disease, autologous and allogeneic hematopoietic stem cell transplant are used as salvage therapy followed by second-line chemotherapy for disease control [170][92]. Patients refractory to primary treatment have a poor prognosis [171][93]. Autologous and allogeneic hematopoietic stem cell transplant are used as salvage therapy with limited efficacy [170][92]. Abraham Avigdor et al. reported a single case of Burkitt lymphoma refractory to multiple chemotherapy regimens and allogenic HCT, where a good response was achieved with salvage CAR T-cell therapy. Given the response, this treatment option could be considered for those with relapsed/refractory disease. [172][94]. Dalton et al. reported the use of low-dose decitabine, a hypomethylating agent. as a novel epigenetic therapeutic agent that can sensitize weakly immunogenic (i.e., EBV+) Burkitt lymphoma expressing type I latency by inducing the expression of more immunogenic proteins such as LMP1, EBNA2, EBNA3A, and EBNA3C. Induction of these proteins allows for EBV-specific T cells to locate and lyse tumor cells [173][95].

4. NK/T-Cell Lymphoma

NK/T-cell lymphoma is a type of non-Hodgkin lymphoma most frequently seen in Latin America and Asia [174][96]. The predominant type is extranodal NK/T-cell lymphoma, nasal type, although other pathologies exist [175][97]. Mutations are common, particularly TP53, DDX3X, STAT3, JAK3, MGA, BCOR, ECSIT, and MCL1 [174][96]. These tumors are strongly associated with EBV [174[96][97],175], although its precise role in generating these tumors is not well explored [176][98].
One way in which EBV contributes to the pathogenesis of NK/T-cell lymphoma is through the actions of LMP1. LMP1 activates PGC1β, a member of the peroxisome proliferator-activated receptor-γ (PPARγ) coactivator-1 (PGC1) family, via activation of NF-κB [177][99]. PGC1β has previously been implicated in tumorigenesis [178,179][100][101]. mRNA and protein levels of PGC1β and its downstream target 8-oxoguanine DNA glycosylase (OGG1), a base excision repair enzyme, were significantly increased in multiple NK/T-cell lines. Mechanistically, it was shown that this effect was mediated by NF-κB activation, which subsequently regulated the PGC1β promoter [177][99]. Furthermore, the disruption of the signaling pathway through the interruption of hexokinase domain component 1 (HKDC1) caused mitochondrial dysfunction and led to the generation of ROS. This led to EBV suppression [177,180][99][102]. The role of LMP1 was further explored by Sun et al. [181][103], who showed that short hairpin RNA (shRNA) targeting LMP1 reduced host migration and invasion. It also promoted apoptosis in the human EBV+ NKTL cell line SNK-6. The authors showed that the LMP1-mediated activation of NF-κB results in the increased expression of elF4E [181][103], a molecule that has been associated with a poor prognosis in multiple malignancies [182,183][104][105]. The LMP1/NF-κB/elF4E axis then increases proliferation, migration, and invasion [181][103]. LMP1 has also been shown to decrease the expression of miR-15a. Suppression of miR-15a allows for increased expression of MYB and cyclin D1 and subsequent increased cell proliferation [184][106].
Interestingly, LMP1 expression in NK/T-cell lymphomas appears to be linked to the TME; monocytes co-cultured with nasal NK/T-cell lymphoma cells stimulated both LMP1 expression and cell proliferation through contact-dependent interactions. This effect was mediated by IL-15 as was evidenced by the fact that treatment with IL-15 antibodies abrogated this effect [185][107].
In summary, LMP1 upregulates PCG1β, which results in the upregulation in the base excision repair enzyme OGG1. Alterations in this signaling pathway led to mitochondrial dysfunction and subsequent ROS activation. In addition, LMP1 plays roles in migration, invasion, cell survival, and cell cycle progression. It also plays a role in manipulating the TME.

Management

Traditional therapies targeting B-cell lymphomas are largely ineffective in NK/T-cell lymphomas [186][108]. The majority of effective therapies include asparaginase [186][108], a compound shown to cause apoptosis in NK/T cells [187][109], or its pegylated form [186][108]. Treatment typically involves chemoradiotherapy [186,188][108][110]. There are multiple potential chemotherapy regiments recommended by the NCCN guidelines, including SMILE (steroid (dexamethasone), methotrexate, ifosfamide, pegaspargase, and etoposide), P-GEMOX (gemcitabine, pegaspargase, and oxaliplatin), and DDGP (dexamethasone, cisplatin, gemcitabine, and pegaspargase) [188][110]. New research has examined EBV as a potential therapeutic target [189][111]. In a phase II trial, 15 patients were treated with baltaleucel-T, a preparation of autologous cytotoxic T lymphocytes specific for EBV. Of the 15 patients, 10 had apparent disease prior to treatment initiation (salvage cohort), and the other 5 had no apparent disease (adjuvant cohort). Of the 10 patients in the salvage cohort, 2 had a partial response and 3 had a complete response. Progression-free survival in this group was 12.3 months on average. two of the five patients in the adjuvant cohort did not experience disease relapse. Additionally, there was no apparent difference between the responders and non-responders in plasma EBV DNA level [189][111].
Additional studies have examined T-cell therapy targeted towards LMP. While patients with T-cell-mediated disease (2 year overall survival (OS) 60%) did not fare as well as patients with B-cell-mediated disease (2 year OS 80%) [190][112], the data did compare favorably to the Center for International Blood and Marrow Transplant Research (CIBMTR) data (2 year OS 36%). Patients received allogeneic hematopoietic stem cell transplant therapy for extranodal NK/T-cell lymphoma [191][113]. While the data were not statistically significant, patients responding to therapy tended to have received T cells with a greater specificity for LMP2/EBV antigens and for those who had higher levels of LMP2-specific T cells [190][112]. A separate trial examined the effectiveness of LMP1 and LMP2A-specific cytotoxic T lymphocytes in a cohort of 10 patients who demonstrated a complete response to therapy. OS at 4 years was 100%, and progression-free survival at 4 years was 90%. Furthermore, levels of IFN-γ-secreting T cells specific for LMP1 and LMP2A were inversely proportional to plasma levels of EBV DNA [192][114].

5. Primary CNS Lymphoma

Primary CNS lymphoma (PCNSL) is a fairly rare and lightly studied tumor limited to the brain, eyes, and cerebrospinal fluid. The vast majority of PCNSLs are DLBCL [193][115], although other histologies have been reported [194][116]. EBV plays a role in the development of a subset of these cases [12][117]. EBV-associated PCNSL was recently shown to differ from PCNSL not associated with EBV infection. EBV-associated PCNSL was significantly less likely to have mutations. Mutations commonly seen in EBV negative PCNSL, such as Myd88, PIM1, and CD79B, were not seen in EBV-associated PCNSL. EBV-associated tumors were also much less likely to be ABC-DLBCL [12][117]. This finding was confirmed by Radke et al. [195][118], who found HLA-DRB and immunoglobulin loci to be the only frequent mutations seen in EBV+ cases. Notably, EBV status has a marked impact on survival, with EBV+ patients having a significantly higher risk of death [196][119]. In summary, while more research is required, EBV has been linked to primary CNS lymphoma. Evidence supporting this fact includes differential mutation types and rates between EBV+ and EBV− CNS lymphomas. EBV status also has significant implications in overall survival.

Management

EBV-associated PCNSL in the immunosuppressed is its own separate entity compared to EBV−, HIV− PCNSL. Prospective therapies ideally are capable of penetrating the blood–brain barrier, interrupting EBV-mediated oncogenesis, and targeting EBV antigens [12][117]. The regimens used in non-CNS lymphoma, such as R-CHOP, are ineffective in PCNSL due to inadequate penetration of the blood–brain barrier [197][120]. Current guidelines suggest that rituximab and high-dose methotrexate should be a part of induction therapy [193][115]. The different regimes used for induction include R-MVP (rituximab, HD-MTX, vincristine, and procarbazine; R-MT (rituximab, HD-MTX, and temozolomide); MATRix (thiotepa, rituximab and HD-MTX, high-dose cytarabine) [193][115]. Relapsed/refractory cases have poor prognosis, and no optimal therapy has been established [193,198][115][121]. Currently, MTX salvage therapy is used, but several prospective studies involving combination regimens (rituximab and temozolomide) [199][122] and single agents such as pemetrexed, topotecan, temozolomide, and rituximab have shown acceptable objective response rates [200,201,202,203][123][124][125][126]. Ibrutinib (BTK-inhibitor) has shown impressive phase I efficacy in recurrent/refractory PCNSL [198][121]. Using EBV+ blood donors, Haque et al. generated EBV-specific cytotoxic T lymphocytes to treat EBV+ PTLD with promising results [204][127]. It is likely that EBV-specific CTL can be utilized in treating other EBV-associated malignancies [205][128]. A phase I Australasian Leukemia/Lymphoma Group clinical trial is also examining the possibility of incorporating EBV-specific third-party T cells (ACTRN12618001541291) in treatment regimens [12][117]. Slobod et al. had promising results treating two patients with HIV-associated PCNSL [206][129].

References

  1. Beltran, B.E.; Castro, D.; Paredes, S.; Miranda, R.N.; Castillo, J.J. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 2020, 95, 435–445.
  2. Oyama, T.; Ichimura, K.; Suzuki, R.; Suzumiya, J.; Ohshima, K.; Yatabe, Y.; Yokoi, T.; Kojima, M.; Kamiya, Y.; Taji, H.; et al. Senile EBV+ B-cell lymphoproliferative disorders: A clinicopathologic study of 22 patients. Am. J. Surg. Pathol. 2003, 27, 16–26.
  3. Sakakibara, A.; Kohno, K.; Ishikawa, E.; Suzuki, Y.; Shimada, S.; Eladl, A.E.; Elsayed, A.A.; Daroontum, T.; Satou, A.; Takahara, T.; et al. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV+ lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142. Pathol. Int. 2020, 70, 481–492.
  4. Sadighi Akha, A.A. Aging and the immune system: An overview. J. Immunol. Methods 2018, 463, 21–26.
  5. Nan, F.F.; Zhang, L.; Li, L.; Li, X.; Sun, Z.C.; Zhang, X.D.; Li, Z.M.; Li, S.C.; Jia, S.S.; Xiao, S.; et al. Clinical features and survival impact of EBV-positive diffuse large B-Cell lymphoma with different age cutoffs. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 8947–8956.
  6. Monabati, A.; Vahedi, A.; Safaei, A.; Noori, S.; Mokhtari, M.; Vahedi, L.; Zamani, M. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age? Asian Pac. J. Cancer Prev. 2016, 17, 2285–2289.
  7. Anastasiadou, E.; Stroopinsky, D.; Alimperti, S.; Jiao, A.L.; Pyzer, A.R.; Cippitelli, C.; Pepe, G.; Severa, M.; Rosenblatt, J.; Etna, M.P.; et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 2019, 33, 132–147.
  8. Wang, X.; Li, J.; Dong, K.; Lin, F.; Long, M.; Ouyang, Y.; Wei, J.; Chen, X.; Weng, Y.; He, T.; et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015, 27, 443–452.
  9. Green, J.A.; Cyster, J.G. S1PR2 links germinal center confinement and growth regulation. Immunol. Rev. 2012, 247, 36–51.
  10. Stelling, A.; Hashwah, H.; Bertram, K.; Manz, M.G.; Tzankov, A.; Muller, A. The tumor suppressive TGF-beta/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood 2018, 131, 2235–2246.
  11. Vockerodt, M.; Vrzalikova, K.; Ibrahim, M.; Nagy, E.; Margielewska, S.; Hollows, R.; Lupino, L.; Tooze, R.; Care, M.; Simmons, W.; et al. Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma. J. Pathol. 2019, 248, 142–154.
  12. Sommermann, T.; Yasuda, T.; Ronen, J.; Wirtz, T.; Weber, T.; Sack, U.; Caeser, R.; Zhang, J.; Li, X.; Chu, V.T.; et al. Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis. Proc. Natl. Acad. Sci. USA 2020, 117, 14421–14432.
  13. Vrzalikova, K.; Vockerodt, M.; Leonard, S.; Bell, A.; Wei, W.; Schrader, A.; Wright, K.L.; Kube, D.; Rowe, M.; Woodman, C.B.; et al. Down-regulation of BLIMP1alpha by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: Implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 2011, 117, 5907–5917.
  14. Ma, S.D.; Tsai, M.H.; Romero-Masters, J.C.; Ranheim, E.A.; Huebner, S.M.; Bristol, J.A.; Delecluse, H.J.; Kenney, S.C. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential. J. Virol. 2017, 91, 7.
  15. Nagel, S.; MacLeod, R.A.F.; Meyer, C.; Kaufmann, M.; Drexler, H.G. NKL homeobox gene activities in B-cell development and lymphomas. PLoS ONE 2018, 13, e0205537.
  16. Nagel, S.; Uphoff, C.C.; Dirks, W.G.; Pommerenke, C.; Meyer, C.; Drexler, H.G. Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL. PLoS ONE 2019, 14, e0216898.
  17. Montes-Moreno, S.; Odqvist, L.; Diaz-Perez, J.A.; Lopez, A.B.; de Villambrosia, S.G.; Mazorra, F.; Castillo, M.E.; Lopez, M.; Pajares, R.; Garcia, J.F.; et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod. Pathol. 2012, 25, 968–982.
  18. Chabay, P. Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma. Cancers 2021, 13, 2717.
  19. Malpica, L.; Marques-Piubelli, M.L.; Beltran, B.E.; Chavez, J.C.; Miranda, R.N.; Castillo, J.J. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2022, 97, 951–965.
  20. Murthy, S.L.; Hitchcock, M.A.; Endicott-Yazdani, T.R.; Watson, J.T.; Krause, J.R. Epstein-Barr virus-positive diffuse large B-cell lymphoma. Bayl. Univ. Med. Cent. Proc. 2017, 30, 443–444.
  21. Pei, Y.; Wong, J.H.Y.; Robertson, E.S. Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas. Cancers 2020, 12, 2565.
  22. Yoon, S.E.; Kim, S.J.; Yoon, D.H.; Koh, Y.; Mun, Y.C.; Do, Y.R.; Choi, Y.S.; Yang, D.H.; Kim, M.K.; Lee, G.W.; et al. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): Results of the final analysis. Ann. Hematol. 2020, 99, 1283–1291.
  23. Tilly, H.; Morschhauser, F.; Sehn, L.H.; Friedberg, J.W.; Trneny, M.; Sharman, J.P.; Herbaux, C.; Burke, J.M.; Matasar, M.; Rai, S.; et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022, 386, 351–363.
  24. Zou, P.; Kawada, J.; Pesnicak, L.; Cohen, J.I. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J. Virol. 2007, 81, 10029–10036.
  25. Zhang, L.H.; Kosek, J.; Wang, M.; Heise, C.; Schafer, P.H.; Chopra, R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br. J. Haematol. 2013, 160, 487–502.
  26. Yilmaz, E.; Lakhotia, R.; Pittaluga, S.; Muppidi, J.; Phelan, J.; Evans, S.; Pradhan, A.; Hillsman, A.; Steinberg, S.; Jaffe, E.S.; et al. Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas. Blood 2021, 138, 4504.
  27. Leen, A.M.; Rooney, C.M.; Foster, A.E. Improving T cell therapy for cancer. Annu. Rev. Immunol. 2007, 25, 243–265.
  28. Sattva, N.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.; Miklos, D.; Jacobson, C.; Braunshweig, I.; Oluwole, O.; Siddiqui, T.; Lin, Y.; et al. Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. Blood 2016, 128, LBA-6.
  29. Wudhikarn, K.; Alarcon Tomas, A.; Flynn, J.R.; Devlin, S.M.; Brower, J.; Bachanova, V.; Nastoupil, L.J.; McGuirk, J.P.; Maziarz, R.T.; Oluwole, O.O.; et al. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2022.
  30. Viracta Therapeutics, Inc. An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas. 2023. Available online: https://clinicaltrials.gov/ct2/show/NCT05011058 (accessed on 8 February 2023).
  31. Haverkos, B.M.; Alpdogan, O.; Baiocchi, R.; Brammer, J.E.; Feldman, T.; Capra, M.; Brem, E.A.; Nair, S.M.; Scheinberg, P.; Pereira, J.; et al. Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study. Blood 2021, 138, 623.
  32. The First Affiliated Hospital with Nanjing Medical University. Sintilimab in Combination With R-CHOP in Patients With Treatment-Naive EBV-Positive DLBCL, NOS. 2023. Available online: https://clinicaltrials.gov/ct2/show/NCT04181489 (accessed on 9 February 2023).
  33. Aggarwal, P.; Limaiem, F. Reed sternberg cells. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022.
  34. Murray, P.G.; Young, L.S. An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood 2019, 134, 591–596.
  35. Stein, H.; Herbst, H.; Anagnostopoulos, I.; Niedobitek, G.; Dallenbach, F.; Kratzsch, H.C. The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann. Oncol. 1991, 2 (Suppl. S2), 33–38.
  36. Weniger, M.A.; Kuppers, R. Molecular biology of Hodgkin lymphoma. Leukemia 2021, 35, 968–981.
  37. Mundo, L.; Del Porro, L.; Granai, M.; Siciliano, M.C.; Mancini, V.; Santi, R.; Marcar, L.; Vrzalikova, K.; Vergoni, F.; Di Stefano, G.; et al. Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: Expanding the landscape of EBV-related lymphomas. Mod. Pathol. 2020, 33, 2637.
  38. Huppmann, A.R.; Nicolae, A.; Slack, G.W.; Pittaluga, S.; Davies-Hill, T.; Ferry, J.A.; Harris, N.L.; Jaffe, E.S.; Hasserjian, R.P. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am. J. Surg. Pathol. 2014, 38, 316–324.
  39. Kanda, T. EBV-Encoded Latent Genes. Adv. Exp. Med. Biol. 2018, 1045, 377–394.
  40. Vockerodt, M.; Morgan, S.L.; Kuo, M.; Wei, W.; Chukwuma, M.B.; Arrand, J.R.; Kube, D.; Gordon, J.; Young, L.S.; Woodman, C.B.; et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin’s Reed-Sternberg-like phenotype. J. Pathol. 2008, 216, 83–92.
  41. Hertel, C.B.; Zhou, X.G.; Hamilton-Dutoit, S.J.; Junker, S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002, 21, 4908–4920.
  42. Aravinth, S.P.; Rajendran, S.; Li, Y.; Wu, M.; Yi Wong, A.H.; Schwarz, H. Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway. Leuk. Lymphoma 2019, 60, 2697–2704.
  43. Ho, W.T.; Pang, W.L.; Chong, S.M.; Castella, A.; Al-Salam, S.; Tan, T.E.; Moh, M.C.; Koh, L.K.; Gan, S.U.; Cheng, C.K.; et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 2013, 73, 652–661.
  44. Jorapur, A.; Marshall, L.A.; Jacobson, S.; Xu, M.; Marubayashi, S.; Zibinsky, M.; Hu, D.X.; Robles, O.; Jackson, J.J.; Baloche, V.; et al. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS Pathog. 2022, 18, e1010200.
  45. Nakayama, T.; Hieshima, K.; Nagakubo, D.; Sato, E.; Nakayama, M.; Kawa, K.; Yoshie, O. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J. Virol. 2004, 78, 1665–1674.
  46. Higuchi, T.; Matsuo, K.; Hashida, Y.; Kitahata, K.; Ujihara, T.; Taniguchi, A.; Yoshie, O.; Nakayama, T.; Daibata, M. Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells. Cancer Lett. 2019, 453, 184–192.
  47. Lin, H.C.; Chang, Y.; Chen, R.Y.; Hung, L.Y.; Chen, P.C.; Chen, Y.P.; Medeiros, L.J.; Chiang, P.M.; Chang, K.C. Epstein-Barr virus latent membrane protein-1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy. Cancer Sci. 2021, 112, 1589–1602.
  48. Wu, J.; Liu, H.; Hu, T.; Wang, S. Gene expression trend changes in breast cancer populations over two decades: Insights from The Cancer Genome Atlas database. Hereditas 2022, 159, 18.
  49. Nagai, L.A.E.; Park, S.J.; Nakai, K. Analyzing the 3D chromatin organization coordinating with gene expression regulation in B-cell lymphoma. BMC Med. Genom. 2019, 11, 127.
  50. Spina, V.; Bruscaggin, A.; Cuccaro, A.; Martini, M.; Di Trani, M.; Forestieri, G.; Manzoni, M.; Condoluci, A.; Arribas, A.; Terzi-Di-Bergamo, L.; et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018, 131, 2413–2425.
  51. Portis, T.; Dyck, P.; Longnecker, R. Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003, 102, 4166–4178.
  52. Anderson, L.J.; Longnecker, R. Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood 2009, 113, 108–116.
  53. Incrocci, R.; McAloon, J.; Montesano, M.; Bardahl, J.; Vagvala, S.; Stone, A.; Swanson-Mungerson, M. Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-kappaB in B-cell lymphomas to increase MIP-1alpha production. J. Med. Virol. 2019, 91, 845–855.
  54. Vrzalikova, K.; Pugh, M.; Mundo, L.; Murray, P. The contributions of ebv to the pathogenesis of classical hodgkin lymphoma. Ann. Lymphoma 2021, 5, 30.
  55. Flavell, J.R.; Baumforth, K.R.; Wood, V.H.; Davies, G.L.; Wei, W.; Reynolds, G.M.; Morgan, S.; Boyce, A.; Kelly, G.L.; Young, L.S.; et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008, 111, 292–301.
  56. Baumforth, K.R.; Birgersdotter, A.; Reynolds, G.M.; Wei, W.; Kapatai, G.; Flavell, J.R.; Kalk, E.; Piper, K.; Lee, S.; Machado, L.; et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin’s lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am. J. Pathol. 2008, 173, 195–204.
  57. Ansell, S.M. Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin. Proc. 2015, 90, 1574–1583.
  58. Khan, G.; Fitzmaurice, C.; Naghavi, M.; Ahmed, L.A. Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990–2017. BMJ Open 2020, 10, e037505.
  59. Engert, A. Treatment of elderly Hodgkin lymphoma patients. Hematol. Oncol. 2019, 37 (Suppl. S1), 92–94.
  60. Jarrett, R.F.; Stark, G.L.; White, J.; Angus, B.; Alexander, F.E.; Krajewski, A.S.; Freeland, J.; Taylor, G.M.; Taylor, P.R.; for the Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group; et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study. Blood 2005, 106, 2444–2451.
  61. Green, M.R.; Rodig, S.; Juszczynski, P.; Ouyang, J.; Sinha, P.; O’Donnell, E.; Neuberg, D.; Shipp, M.A. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin. Cancer Res. 2012, 18, 1611–1618.
  62. Prince, H.M.; Hutchings, M.; Domingo-Domenech, E.; Eichenauer, D.A.; Advani, R. Anti-CD30 antibody-drug conjugate therapy in lymphoma: Current knowledge, remaining controversies, and future perspectives. Ann. Hematol. 2023, 102, 13–29.
  63. Advani, R.H.; Moskowitz, A.J.; Bartlett, N.L.; Vose, J.M.; Ramchandren, R.; Feldman, T.A.; LaCasce, A.S.; Christian, B.A.; Ansell, S.M.; Moskowitz, C.H.; et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021, 138, 427–438.
  64. Kersten, M.J.; Driessen, J.; Zijlstra, J.M.; Plattel, W.J.; Morschhauser, F.; Lugtenburg, P.J.; Brice, P.; Hutchings, M.; Gastinne, T.; Liu, R.; et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: The phase II HOVON/LLPC Transplant BRaVE study. Haematologica 2021, 106, 1129–1137.
  65. Straus, D.J.; Dlugosz-Danecka, M.; Alekseev, S.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K.J.; Bartlett, N.L.; et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020, 135, 735–742.
  66. Meier, J.A.; Savoldo, B.; Grover, N.S. The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma. J. Pers. Med. 2022, 12, 197.
  67. Ramos, C.A.; Grover, N.S.; Beaven, A.W.; Lulla, P.D.; Wu, M.F.; Ivanova, A.; Wang, T.; Shea, T.C.; Rooney, C.M.; Dittus, C.; et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J. Clin. Oncol. 2020, 38, 3794–3804.
  68. Zhang, P.; Yang, X.; Cao, Y.; Wang, J.; Zhou, M.; Chen, L.; Wei, J.; Mao, Z.; Wang, D.; Xiao, Y.; et al. Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma. Exp. Hematol. Oncol. 2022, 11, 72.
  69. Taylor, G.S.; Long, H.M.; Brooks, J.M.; Rickinson, A.B.; Hislop, A.D. The immunology of Epstein-Barr virus-induced disease. Annu. Rev. Immunol. 2015, 33, 787–821.
  70. Cui, X.; Snapper, C.M. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front. Immunol. 2021, 12, 734471.
  71. Jiang, L.; Xie, C.; Lung, H.L.; Lo, K.W.; Law, G.L.; Mak, N.K.; Wong, K.L. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics 2018, 8, 5307–5319.
  72. Roschewski, M.; Staudt, L.M.; Wilson, W.H. Burkitt’s Lymphoma. N. Engl. J. Med. 2022, 387, 1111–1122.
  73. Epstein, M.A.; Achong, B.G.; Barr, Y.M. Virus Particles in Cultured Lymphoblasts from Burkitt’s Lymphoma. Lancet 1964, 1, 702–703.
  74. Shannon-Lowe, C.; Rickinson, A. The Global Landscape of EBV-Associated Tumors. Front. Oncol. 2019, 9, 713.
  75. Summerauer, A.M.; Jaggi, V.; Ogwang, R.; Traxel, S.; Colombo, L.; Amundsen, E.; Eyer, T.; Subramanian, B.; Fehr, J.; Mantel, P.Y.; et al. Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID seems to play a major mutagenic role in Burkitt lymphoma. Eur. J. Immunol. 2022, 52, 1273–1284.
  76. Marques-Piubelli, M.L.; Salas, Y.I.; Pachas, C.; Becker-Hecker, R.; Vega, F.; Miranda, R.N. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: A review. Pathology 2020, 52, 40–52.
  77. Rochford, R. Reframing Burkitt lymphoma: Virology not epidemiology defines clinical variants. Ann. Lymphoma 2021, 5, 22.
  78. Noh, K.W.; Park, J.; Kang, M.S. Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth. BMB Rep. 2016, 49, 226–231.
  79. Wang, R.; Wang, J.; Zhang, N.; Wan, Y.; Liu, Y.; Zhang, L.; Pan, S.; Zhang, C.; Zhang, H.; Cao, Y. The interaction between Vav1 and EBNA1 promotes survival of Burkitt’s lymphoma cells by down-regulating the expression of Bim. Biochem. Biophys. Res. Commun. 2019, 511, 787–793.
  80. Prieto-Sanchez, R.M.; Hernandez, J.A.; Garcia, J.L.; Gutierrez, N.C.; San Miguel, J.; Bustelo, X.R.; Hernandez, J.M. Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. Br. J. Haematol. 2006, 133, 642–645.
  81. Anderton, E.; Yee, J.; Smith, P.; Crook, T.; White, R.E.; Allday, M.J. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: Clues to the pathogenesis of Burkitt’s lymphoma. Oncogene 2008, 27, 421–433.
  82. Piccaluga, P.P.; Navari, M.; De Falco, G.; Ambrosio, M.R.; Lazzi, S.; Fuligni, F.; Bellan, C.; Rossi, M.; Sapienza, M.R.; Laginestra, M.A.; et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget 2016, 7, 224–240.
  83. Vereide, D.T.; Seto, E.; Chiu, Y.F.; Hayes, M.; Tagawa, T.; Grundhoff, A.; Hammerschmidt, W.; Sugden, B. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 2014, 33, 1258–1264.
  84. Asadi, M.; Taghizadeh, S.; Kaviani, E.; Vakili, O.; Taheri-Anganeh, M.; Tahamtan, M.; Savardashtaki, A. Caspase-3: Structure, function, and biotechnological aspects. Biotechnol. Appl. Biochem. 2022, 69, 1633–1645.
  85. Harold, C.; Cox, D.; Riley, K.J. Epstein-Barr viral microRNAs target caspase 3. Virol. J. 2016, 13, 145.
  86. Zhang, Y.M.; Yu, Y.; Zhao, H.P. EBV-BART-6-3p and cellular microRNA-197 compromise the immune defense of host cells in EBV-positive Burkitt lymphoma. Mol. Med. Rep. 2017, 15, 1877–1883.
  87. Zhou, L.; Bu, Y.; Liang, Y.; Zhang, F.; Zhang, H.; Li, S. Epstein-Barr Virus (EBV)-BamHI-A Rightward Transcript (BART)-6 and Cellular MicroRNA-142 Synergistically Compromise Immune Defense of Host Cells in EBV-Positive Burkitt Lymphoma. Med. Sci. Monit. 2016, 22, 4114–4120.
  88. Yehia, L.; Keel, E.; Eng, C. The Clinical Spectrum of PTEN Mutations. Annu. Rev. Med. 2020, 71, 103–116.
  89. Crombie, J.; LaCasce, A. The treatment of Burkitt lymphoma in adults. Blood 2021, 137, 743–750.
  90. Evens, A.M.; Danilov, A.; Jagadeesh, D.; Sperling, A.; Kim, S.H.; Vaca, R.; Wei, C.; Rector, D.; Sundaram, S.; Reddy, N.; et al. Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers. Blood 2021, 137, 374–386.
  91. Lv, K.; Yin, T.; Yu, M.; Chen, Z.; Zhou, Y.; Li, F. Treatment Advances in EBV Related Lymphoproliferative Diseases. Front. Oncol. 2022, 12, 838817.
  92. Maramattom, L.V.; Hari, P.; Burns, L.J.; Carreras, J.; Arcese, W.; Cairo, M.S.; Costa, L.; Fenske, T.; Lill, M.; Freytes, C.; et al. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: A report from the center for international blood and marrow transplant research. Biol. Blood Marrow Transplant. 2013, 19, 173–179.
  93. Short, N.J.; Kantarjian, H.M.; Ko, H.; Khoury, J.D.; Ravandi, F.; Thomas, D.A.; Garcia-Manero, G.; Khouri, M.; Cortes, J.E.; Wierda, W.G.; et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am. J. Hematol. 2017, 92, E114–E117.
  94. Avigdor, A.; Shouval, R.; Jacoby, E.; Davidson, T.; Shimoni, A.; Besser, M.; Nagler, A. CAR T cells induce a complete response in refractory Burkitt Lymphoma. Bone Marrow Transpl. 2018, 53, 1583–1585.
  95. Dalton, T.; Doubrovina, E.; Pankov, D.; Reynolds, R.; Scholze, H.; Selvakumar, A.; Vizconde, T.; Savalia, B.; Dyomin, V.; Weigel, C.; et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood 2020, 135, 1870–1881.
  96. Wang, H.; Fu, B.B.; Gale, R.P.; Liang, Y. NK-/T-cell lymphomas. Leukemia 2021, 35, 2460–2468.
  97. Swerdlow, S.H.; Campo, E.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016, 127, 2375–2390.
  98. Montes-Mojarro, I.A.; Fend, F.; Quintanilla-Martinez, L. EBV and the Pathogenesis of NK/T Cell Lymphoma. Cancers 2021, 13, 1414.
  99. Feng, J.; Chen, Q.; Zhang, P.; Huang, X.; Xie, W.; Zhang, H.; Yao, P. Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1beta Signaling Pathway. Stem Cell Rev. Rep. 2021, 17, 1486–1499.
  100. Deblois, G.; St-Pierre, J.; Giguere, V. The PGC-1/ERR signaling axis in cancer. Oncogene 2013, 32, 3483–3490.
  101. Zhang, H.; Li, L.; Chen, Q.; Li, M.; Feng, J.; Sun, Y.; Zhao, R.; Zhu, Y.; Lv, Y.; Zhu, Z.; et al. PGC1beta regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism. Mol. Oncol. 2018, 12, 1579–1595.
  102. Chen, Q.; Feng, J.; Wu, J.; Yu, Z.; Zhang, W.; Chen, Y.; Yao, P.; Zhang, H. HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression. Leukemia 2020, 34, 2736–2748.
  103. Sun, L.; Zhao, Y.; Shi, H.; Ma, C.; Wei, L. LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF-kappaB pathway. Oncol. Rep. 2015, 34, 3264–3271.
  104. Dong, Q.; Dong, L.; Liu, S.; Kong, Y.; Zhang, M.; Wang, X. Tumor-Derived Exosomal eIF4E as a Biomarker for Survival Prediction in Patients with Non-Small Cell Lung Cancer. Med. Sci. Monit. 2020, 26, e923210.
  105. Li, F.; Sun, H.; Li, Y.; Bai, X.; Dong, X.; Zhao, N.; Meng, J.; Sun, B.; Zhang, D. High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer. BMC Cancer 2021, 21, 1305.
  106. Komabayashi, Y.; Kishibe, K.; Nagato, T.; Ueda, S.; Takahara, M.; Harabuchi, Y. Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma. Am. J. Hematol. 2014, 89, 25–33.
  107. Ishii, H.; Takahara, M.; Nagato, T.; Kis, L.L.; Nagy, N.; Kishibe, K.; Harabuchi, Y.; Klein, E. Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int. J. Cancer 2012, 130, 48–58.
  108. Tse, E.; Zhao, W.L.; Xiong, J.; Kwong, Y.L. How we treat NK/T-cell lymphomas. J. Hematol. Oncol. 2022, 15, 74.
  109. Ando, M.; Sugimoto, K.; Kitoh, T.; Sasaki, M.; Mukai, K.; Ando, J.; Egashira, M.; Schuster, S.M.; Oshimi, K. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br. J. Haematol. 2005, 130, 860–868.
  110. National Comprehensive Cancer Network. T-Cell Lymphomas (Version 1.2023). Available online: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf (accessed on 25 February 2023).
  111. Kim, W.S.; Oki, Y.; Kim, S.J.; Yoon, S.E.; Ardeshna, K.M.; Lin, Y.; Ruan, J.; Porcu, P.; Brammer, J.E.; Jacobsen, E.D.; et al. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: Results of a multicenter study. Ann. Hematol. 2021, 100, 2529–2539.
  112. McLaughlin, L.P.; Rouce, R.; Gottschalk, S.; Torrano, V.; Carrum, G.; Wu, M.F.; Hoq, F.; Grilley, B.; Marcogliese, A.M.; Hanley, P.J.; et al. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 2018, 132, 2351–2361.
  113. Kanate, A.S.; DiGilio, A.; Ahn, K.W.; Al Malki, M.; Jacobsen, E.; Steinberg, A.; Hamerschlak, N.; Kharfan-Dabaja, M.; Salit, R.; Ball, E.; et al. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: A CIBMTR analysis. Br. J. Haematol. 2018, 182, 916–920.
  114. Cho, S.G.; Kim, N.; Sohn, H.J.; Lee, S.K.; Oh, S.T.; Lee, H.J.; Cho, H.I.; Yim, H.W.; Jung, S.E.; Park, G.; et al. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs. Mol. Ther. 2015, 23, 1401–1409.
  115. Grommes, C.; DeAngelis, L.M. Primary CNS Lymphoma. J. Clin. Oncol. 2017, 35, 2410–2418.
  116. Henkenberens, C.; Franzke, A.; Raab, P.; Oschlies, I.; Klapper, W.; Christiansen, H. Primary EBV-positive Hodgkin’s lymphoma of the CNS under azathioprine treatment: Case report and review of the literature. Strahlenther. Onkol. 2014, 190, 847–852.
  117. Gandhi, M.K.; Hoang, T.; Law, S.C.; Brosda, S.; O’Rourke, K.; Tobin, J.W.D.; Vari, F.; Murigneux, V.; Fink, L.; Gunawardana, J.; et al. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood 2021, 137, 1468–1477.
  118. Radke, J.; Ishaque, N.; Koll, R.; Gu, Z.; Schumann, E.; Sieverling, L.; Uhrig, S.; Hubschmann, D.; Toprak, U.H.; Lopez, C.; et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat. Commun. 2022, 13, 2558.
  119. Prado, I.P.; Barbiero, F.; Baehring, J.; Becker, K.; Corbin, Z. The impact of Epstein-Barr virus status on primary CNS lymphoma survival. J. Clin. Oncol. 2019, 37, e13528.
  120. Ferreri, A.J.M.; Calimeri, T.; Conte, G.M.; Cattaneo, D.; Fallanca, F.; Ponzoni, M.; Scarano, E.; Curnis, F.; Nonis, A.; Lopedote, P.; et al. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-alpha in primary CNS lymphoma. Blood 2019, 134, 252–262.
  121. Grommes, C.; Pastore, A.; Palaskas, N.; Tang, S.S.; Campos, C.; Schartz, D.; Codega, P.; Nichol, D.; Clark, O.; Hsieh, W.Y.; et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017, 7, 1018–1029.
  122. Nayak, L.; Abrey, L.E.; Drappatz, J.; Gilbert, M.R.; Reardon, D.A.; Wen, P.Y.; Prados, M.; Deangelis, L.M.; Omuro, A.; for the North American Brain Tumor Consortium. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma 2013, 54, 58–61.
  123. Raizer, J.J.; Rademaker, A.; Evens, A.M.; Rice, L.; Schwartz, M.; Chandler, J.P.; Getch, C.C.; Tellez, C.; Grimm, S.A. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer 2012, 118, 3743–3748.
  124. Fischer, L.; Thiel, E.; Klasen, H.A.; Birkmann, J.; Jahnke, K.; Martus, P.; Korfel, A. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol. 2006, 17, 1141–1145.
  125. Reni, M.; Zaja, F.; Mason, W.; Perry, J.; Mazza, E.; Spina, M.; Bordonaro, R.; Ilariucci, F.; Faedi, M.; Corazzelli, G.; et al. Temozolomide as salvage treatment in primary brain lymphomas. Br. J. Cancer 2007, 96, 864–867.
  126. Batchelor, T.T.; Grossman, S.A.; Mikkelsen, T.; Ye, X.; Desideri, S.; Lesser, G.J. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011, 76, 929–930.
  127. Haque, T.; Wilkie, G.M.; Jones, M.M.; Higgins, C.D.; Urquhart, G.; Wingate, P.; Burns, D.; McAulay, K.; Turner, M.; Bellamy, C.; et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007, 110, 1123–1131.
  128. Davis, J.E.; Moss, D.J. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004, 63, 285–292.
  129. Slobod, K.S.; Taylor, G.H.; Sandlund, J.T.; Furth, P.; Helton, K.J.; Sixbey, J.W. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000, 356, 1493–1494.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback